Drug
Men1703
Men1703: highest development phase Phase 2, developed by Menarini, United Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Menarini, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| MEN1703 NCT06534437 | Phase 2 | Non-Hodgkin Lymphoma, B-cell |
| MEN1703 NCT03008187 | Phase 1/2 | Acute Myeloid Leukemia |
Latest
No recent events.
Follow Men1703 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.